compounded semaglutide fda enforcement news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Safe use of compounded GLP
Description
Abroad, seek the nearest emergency medical service
The planned cardiovascular outcomes trial will help answer whether this translates to any longer-term risk
In addition to managing side effects, lifestyle changes can improve how well GLP-1 agonists work and enhance your overall experience
Retatrutide is currently available for research purposes and is not yet FDA-approved for obesity treatment
Diabetologia 51 (12), 22632270
It lowers blood sugar by reducing glucagon levels after meals
